LEGN vs Peers Stock Comparison

Legend Biotech Prices as of Oct 26, 2026 Peers: Industry group
LEGN Legend Biotech Corp
$20.39 +6.7% 1M -36.0% 1Y
Market cap
$3.99B
P/E
–
Revenue (TTM)
$1.27B
Div. yield
–
Gene and Cell Therapy Healthcare

Percentile Scorecard

LEGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisLEGN
Valuation 89 #71 of 626
Growth 97 #21 of 604
Profitability 80 #114 of 555
Financial Health 54 #306 of 658
Shareholder Returns 43 #212 of 368
Overall 72
  • LEGN ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodLEGNSPY
1 month +6.7% -0.8%
3 months +5.8% +3.5%
6 months -13.8% +7.0%
Year to date -6.2% +12.2%
1 year -36.0% +13.0%
3 years -68.0% +86.3%
3 years, per year -31.6% +23.1%
5 years -60.6% +68.6%
5 years, per year -17.0% +11.0%

Risk

MeasureLEGNSPY
Volatility, 1Y 72.1% 12.7%
Downside volatility, 1Y 62.7% 12.7%
Beta vs S&P 500, 1Y 0.41 1.00
Return / volatility, 1Y -0.50 1.02
Max drawdown, 5Y -78.2% -25.4%
From 52-week high -43.8% -1.8%
52-week high $36.28 $779.14
52-week low $16.65 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleLEGN
P/E now vs peer median -41.0xmedian 17.1x
P/S now vs peer median 3.0xmedian 8.8x
EV/EBITDA now vs peer median -175.9xmedian 17.1x
P/FCF now vs peer median -58.2xmedian 18.0x
P/B now vs peer median 3.1xmedian 2.1x
PEG now vs peer median -0.87median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsLEGN
Revenue $1.27B
Gross profit $727.10M
Operating income -$55.25M
Net income -$80.39M
Free cash flow -$64.60M
R&D $396.15M
EPS (diluted) $-0.50
Cash & equivalents $672.90M
Total debt $1.06B
Shares (diluted) 184.32M
Enterprise value $1.48B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricLEGN
P/E -41.0x
P/FCF -58.2x
P/Operating cash flow -42.0x
P/S 3.0x
P/B 3.1x
P/Tangible book 3.1x
EV/EBITDA -175.9x
EV/EBIT -58.7x
EV/Revenue 2.6x
EV/FCF -50.2x
EV/Operating cash flow -36.3x
PEG (3Y EPS CAGR) -0.87

Growth

14 metrics
MetricLEGN
Revenue growth (1Y) 59.5%
Revenue CAGR (3Y) 97.6%
Gross profit growth (1Y) 42.4%
Gross profit CAGR (3Y) 147.5%
Operating income growth (1Y) 75.3%
Operating income CAGR (3Y) 49.1%
Net income growth (1Y) 75.3%
Net income CAGR (3Y) 46.7%
EPS growth (1Y) 72.0%
EPS CAGR (3Y) 47.0%
Operating cash flow growth (1Y) 67.5%
Operating cash flow CAGR (3Y) 37.1%
Free cash flow growth (1Y) 77.8%
Free cash flow CAGR (3Y) 44.5%

Profitability

14 metrics
MetricLEGN
Gross margin 57.2%
EBITDA margin -1.5%
Operating margin -4.3%
Pretax margin -4.4%
Net margin -7.2%
FCF margin -5.1%
Operating cash flow margin -7.0%
Return on equity -8.3%
Return on assets -5.5%
Return on invested capital -4.2%
Return on capital employed -4.3%
Asset turnover 0.8x
Cash conversion (OCF / net income) 1.1x
Stock comp / revenue 5.2%

Financial Health

11 metrics
MetricLEGN
Debt / assets 8.9%
Debt / equity 0.1x
Net debt / EBITDA 28.0x
Debt / FCF -2.4x
Liabilities / assets 29.8%
Equity / assets 70.2%
Interest coverage -4.8x
Current ratio 3.0x
Quick ratio 1.7x
Cash ratio 1.7x
Altman Z-score 6.50

Shareholder Returns

7 metrics
MetricLEGN
Dividend yield –
Net buyback yield -5.7%
Shareholder yield -5.7%
Payout ratio (earnings) –
Payout ratio (FCF) –
Dividend growth (1Y) –
Dividend CAGR (3Y) –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusLEGN
EPS, next fiscal year $-0.04FY2026
Revenue, next fiscal year $1.37BFY2026
Revenue growth, next FY +32.9%FY2026
Revenue growth, the year after +35.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersLEGN
Held by institutions 55.9%
Institutions holding 218
Change in shares held, QoQ +7.3%
Institutions buying 117
Institutions selling 78
Buyers to sellers 1.50

Add a Peer

Largest companies in the same industry

Related Comparisons

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.